Furthermore, Notarangelo and colleagues reported that the exposure of thyroid cancer cells to vemurafenib resulted in a rapid feedback activation of EGFR pathway, and dual EGFR and BRAF blockade induces suppression of ERK signaling, inhibition of cell proliferation, and synthetic lethality [71]. This evidence concerns the gene BRAF and thyroid gland carcinoma.